2026年8月31日至9月1日，G20在美國阿什維爾舉行年內第二次財長和央行行長會議，中國人民銀行行長潘功勝出席並發言。中國人民銀行於9月5日公布，將持續推進貨幣政策框架轉型、完善利率體系，並繼續實施適度寬鬆的貨幣政策。潘功勝亦表示，中國將擴大內需、推進經濟結構轉型升級，並不刻意追求貿易順差。9月21日，中國人民銀行召開外資金融機構座談會，Bank of America、JPMorgan Chase、HSBC及Standard Chartered等共15家機構的負責人參與；潘功勝再次表示會實施適度寬鬆貨幣政策、擴大金融市場雙向開放及優化跨境支付。兩次公布均沒有列明降準、減息、流動性投放規模、執行日期或具體開放措施。
Lilly claims one-third of new oral GLP-1 patients as it begins work on a $6.5 billion US plant
mediumManagement-reported market-share gain combined with a manufacturing-capacity investment
重點摘要 · Key summary
Eli Lilly CEO Dave Ricks told CNBC that Foundayo is being taken by one-third of new GLP-1 pill patients and that its oral-market share is growing week over week. Foundayo entered the US market in April and generated $98 million in second-quarter sales, its first three-month period on the market. Lilly broke ground on Monday for a $6.5 billion manufacturing facility at Generation Park in Houston, which it expects to become operational by 2030 and to produce Foundayo ingredients and other small-molecule medicines. Lilly said in August that it held about 61% of the overall market in the second quarter, while CNBC reports that Novo Nordisk launched an oral product before Lilly. Medicare coverage of obesity drugs began in July, according to CNBC, and Lilly plans additional international launches of Foundayo in the coming months.
你的商機 · Your opportunities
capital立即About 4 hours this week, followed by one
Build a one-page Lilly-versus-Novo evidence sheet using their latest quarterly filings and earnings materials. Record Foundayo revenue, oral prescription share methodology, total obesity-market share, manufacturing capital expenditure and forward guidance; do not treat the CNBC share claim as verified unless a filing or independent prescription dataset supports it.
第一步Download Eli Lilly's second-quarter filing and earnings presentation, then locate the source and definition behind the reported $98 million revenue and 61% overall-market share.
operating立即About 6 to 8 hours for outreach, five ca
Conduct five short calls with insurance executives in your network using the same questions: whether oral obesity drugs are covered, what prior authorization applies, whether Medicare's July change affects commercial formularies, and whether pills are displacing injectables. Summarize the answers into a reimbursement-friction score within two weeks.
第一步Send a five-question interview request to three insurance executives already in your network and ask each for one relevant US-market referral if they lack direct knowledge.